Get the Stockscreener App
10.58
4.46%
-0.53
Delcath Systems Inc stock is traded at $10.58, with a volume of 163.43K.
It is down -4.46% in the last 24 hours and down -10.58% over the past month.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
See More
Previous Close:
$11.11
Open:
$10.96
24h Volume:
163.43K
Relative Volume:
0.22
Market Cap:
$370.80M
Revenue:
$2.07M
Net Income/Loss:
$-47.68M
P/E Ratio:
-3.7518
EPS:
-2.82
Net Cash Flow:
$-31.31M
1W Performance:
+4.16%
1M Performance:
-10.58%
6M Performance:
-34.80%
1Y Performance:
+44.21%
1-Day Range:
$10.52
$11.00
1-Week Range:
$9.87
$11.21
52-Week Range:
$7.36
$18.23
Delcath Systems Inc Stock (DCTH) Company Profile
Name
Delcath Systems Inc
Sector
Industry
Phone
(518) 743-8892
Address
566 QUEENSBURY AVENUE, QUEENSBURY, NY
Compare DCTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DCTH
Delcath Systems Inc
|
10.60 | 380.60M | 2.07M | -47.68M | -31.31M | -2.82 |
|
ABT
Abbott Laboratories
|
129.01 | 228.03B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.88 | 152.09B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
376.01 | 143.98B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.37 | 117.98B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.36 | 45.17B | 5.69B | 1.41B | 577.90M | 6.95 |
Delcath Systems Inc Stock (DCTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-24 | Initiated | Craig Hallum | Buy |
| May-14-24 | Initiated | Stephens | Overweight |
| Jul-26-22 | Resumed | Canaccord Genuity | Buy |
| Dec-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-09-21 | Initiated | Canaccord Genuity | Buy |
| Jan-05-21 | Initiated | BTIG Research | Buy |
| Jun-01-20 | Initiated | Laidlaw | Buy |
View All
Delcath Systems Inc Stock (DCTH) Latest News
H.C. Wainwright Remains Bullish on Delcath Systems (DCTH) - MSN
Are Bears Losing Grip on Delcath Systems Inc.Earnings Risk Summary & Weekly Watchlist of Top Performers - metal.it
12 Best Medical Device Stocks to Buy According to Analysts - Insider Monkey
Delcath Systems: Huge Potential But With The Handbrake On For Now (NASDAQ:DCTH) - Seeking Alpha
Is Delcath Systems Inc. Starting a New UptrendROI Boosting Trade Opportunity Calendar Published - beatles.ru
Delcath Systems Q3 EPS Forecast Decreased by HC Wainwright - Defense World
Will a bounce in Delcath Systems Inc. offer an exitFree Long Hold Safe Return Strategy - Newser
Why Delcath Systems Inc. stock attracts strong analyst attentionDaily Trade Setup Forecast with Confidence - Newser
Real time scanner hits for Delcath Systems Inc. explainedBuy and Hold Position Summary Review - Newser
What MACD and RSI say about Delcath Systems Inc.Predictive Screener for Daily Trade Watch - Newser
Intraday pattern recognizer results for Delcath Systems Inc.Free AI Trading Suggestions With Accuracy Focus - Newser
Is Delcath Systems Inc. a turnaround storyBlue Chip Bargain Alerts - thegnnews.com
Delcath Systems (NASDAQ:DCTH) Price Target Raised to $31.00 - Defense World
Analysts Set Expectations for Delcath Systems Q1 Earnings - Defense World
Delcath Systems (NASDAQ:DCTH) Rating Lowered to “Hold” at Wall Street Zen - Defense World
What makes Delcath Systems Inc. stock price move sharplySwing Trade Signal and Price Prediction - Newser
Delcath outlines 175% projected HEPZATO volume growth and targets up to 28 operational centers by year-end 2025 amid expanding clinical pipeline - MSN
Delcath Systems, Inc. Just Recorded A 200% EPS Beat: Here's What Analysts Are Forecasting Next - simplywall.st
Delcath Systems, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - uk.finance.yahoo.com
Delcath Systems, Inc. (DCTH) Surpasses Q2 Earnings and Revenue Estimates - MSN
Delcath Systems Reports Strong Q2 2025 Results - The Globe and Mail
Delcath Systems Reports Strong Q2 Growth Amid Challenges - The Globe and Mail
Delcath Systems 2025 Q2 Earnings Strong Performance as Net Income Surges 119.6% - AInvest
H.C. Wainwright Maintains Delcath Systems(DCTH.US) With Buy Rating, Raises Target Price to $31 - 富途牛牛
Delcath Systems’ HEPZATO Drives Strong Growth and Expansion, Justifying Buy Rating - TipRanks
Delcath Systems, Inc. (NASDAQ:DCTH) Q2 2025 Earnings Call Transcript - Insider Monkey
Delcath Systems (DCTH) Sees Analyst Target Price Raised by HC Wa - GuruFocus
We Like These Underlying Return On Capital Trends At Delcath Systems (NASDAQ:DCTH) - uk.finance.yahoo.com
Delcath Systems Reports Second Quarter 2025 Results and Business Highlights - BioSpace
Delcath Systems shares rise 4.23% premarket after reporting Q2 earnings beat and revenue growth. - AInvest
Delcath (DCTH) Q2 Revenue Jumps 210% - AOL.com
Delcath Systems shares rise 4.14% after-hours after reporting Q2 earnings beat and net income of USD 2.7 million. - AInvest
Delcath Turns The Corner With Record Sales And Profit - Finimize
Delcath’s Revenue Jumps As Cancer Kit Sales Climb - Finimize
Versus Systems Inc. shares rise 2.18% intraday after Delcath Systems, Inc. reported a net income of USD 2.7 million for Q2 2025. - AInvest
Delcath Systems: Navigating the High-Stakes Gamble of HEPZATO's 200% Volume Growth and 28-Operational-Center Scalability in a Fractured Oncology Market - AInvest
Transcript : Delcath Systems, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Delcath Systems Q2 2025: Contradictions Unveiled on NDRA Impact, Activation Timelines, and European Growth - AInvest
Earnings call transcript: Delcath Systems Q2 2025 earnings beat expectations By Investing.com - Investing.com Nigeria
Earnings call transcript: Delcath Systems Q2 2025 earnings beat expectations - Investing.com India
Delcath Systems Reports Second Quarter 2025 Results and Business Highlights | DCTH Stock News - GuruFocus
Delcath Systems earnings beat by $0.04, revenue topped estimates - Investing.com Canada
Delcath Systems Inc (DCTH) Q2 2025 Earnings: EPS of $0.07 Beats - GuruFocus
Interventional oncology firm Delcath's Q2 revenue beats estimates - MarketScreener
The DCTH Stock Puzzle: Unraveling Delcath Systems Inc’s Fluctuating Performance - investchronicle.com
Will Delcath Systems Inc. rebound enough to break evenCapital Growth Plan for New Investors - Newser
Delcath Systems to Report Q2 Earnings with Expected $0.03 EPS, $23.02M Revenue - AInvest
Visual analytics tools that track Delcath Systems Inc. performancePrice Action Summary and Entry Strategy Guide - Newser
Wall Street Zen Upgrades Delcath Systems (NASDAQ:DCTH) to “Buy” - Defense World
Delcath Systems (DCTH) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Does Delcath Systems Inc. stock perform well during market downturnsCapitalize on market shifts before others do - Jammu Links News
Delcath Systems Inc Stock (DCTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
0.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):